Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLAU


Brief Information

Name:Urokinase plasminogen activator
Target Synonym:PLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC 3.4.21,EC:,U-Plasminogen Activator,EC
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
PLU-H5228 Human Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5229 Human Human PLAU / uPA Protein, His Tag
ACRO Quality

Part of Bioactivity data


Immobilized Human PLAU, His Tag (Cat. No. PLU-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human uPAR, His,Avitag (Cat. No. UPR-H82E7) with a linear range of 0.3-5 ng/mL (QC tested).

Synonym Name



Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Urokinase biosimilar (Sedico) Approved Sedico Angikinase Egypt Pulmonary Embolism; Myocardial Infarction; Thromboembolism Sedico 2014-01-01 Pulmonary Embolism; Myocardial Infarction; Thromboembolism Details
Tisokinase AK-124 Approved Kowa Co Ltd, Asahi Kasei Corp Plasvata, Hapase Japan Myocardial Infarction; Thrombosis null 1991-01-01 Myocardial Infarction; Thrombosis Details
Urokinase biosimilar (Bharat Serums & Vaccines) U-FRAG Approved Bharat Serums And Vaccines Ltd Pulmonary Embolism Details
Nasaruplase GE-0943 Approved Mitsubishi Pharma Corp Tomieze, Thrombolyse Japan Myocardial Infarction; Venous Thrombosis Mitsubishi Pharma Corp 1992-01-01 Myocardial Infarction; Venous Thrombosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Urokinase biosimilar (Suzhou Landing Biological Pharmaceutical) Phase 3 Clinical Suzhou RxD Biopharmaceutical Co Ltd ST Elevation Myocardial Infarction Details
tPA/HisproUK (Thrombolytic Science) TS-01 Phase 2 Clinical Thrombolytic Science Stroke Details
Upamostat Hydrogen Sulphate (Wilex) WX-671; LH-011; RHB-107 Phase 2 Clinical Wilex Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Breast Neoplasms Details
Recombinant human annexin 5 protein (Yabao Pharmaceuticals) SY-005 Phase 2 Clinical Yabao Pharmaceutical Group Co Ltd, Lawson Health Research Institute Sepsis; Coronavirus Infections Details
Recombinant annexin A5 (Annexin Pharmaceuticals) ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5) Phase 2 Clinical Annexin Pharmaceuticals AB Neoplasms; Cardiovascular Diseases; Anemia, Sickle Cell; Retinal Vein Occlusion Details
MSB-03 MSB-03 Phase 1 Clinical Matrisys Rosacea Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message